|Day Low/High||86.46 / 89.34|
|52 Wk Low/High||35.25 / 123.99|
Shares of Exact Sciences has been on the upswing, but the stock price of the cancer screening test firm may be vulnerable.
Our strategy on EXAS shares after the company's latest earnings.
ZTS discovers, develops, manufactures, and markets veterinary vaccines and medicines.
The stock still looks vulnerable to further declines from a technical perspective.
Some good discussions today on the Daily Diary. Look forward to continuing the conversation tomorrow as we look to wrap up a solid week for equities. Market was lackluster today but had a ton of earnings reports to take into account. Not to mention ...
Biotech shares have gained from takeovers in that sector.
Here's a window into what institutional investors may be doing and how to profit from that.
Exact Sciences (EXAS) shares have pulled back in the past month due to a secondary offering and profit taking after a huge run-up.